What is the difference between incretin mimetics and GLP-1 receptor agonists?

GLP-1 receptor agonists (GLP-1RA) is the original term for compounds activating the GLP-1 receptor specifically. 'Incretin mimetics' is a broader class term covering all compounds that mimic incretin hormone actions, including dual agonists (GLP-1R + GIPR, e.g. tirzepatide) and triple agonists (GLP-1R + GIPR + GcgR, e.g. retatrutide). In research literature, 'incretin receptor agonist' is increasingly preferred for multi-receptor compounds to avoid the inaccuracy of calling a dual or triple agonist just a 'GLP-1 receptor agonist.' In practice, both terms appear for semaglutide/liraglutide (single receptor), while tirzepatide and retatrutide are usually called dual or triple agonists rather than GLP-1RAs.

An incretin is a gut hormone released after nutrient ingestion that stimulates insulin secretion in a glucose-dependent manner (only when blood glucose is elevated). The two main incretins are GLP-1 (glucagon-like peptide-1, secreted by L-cells in the distal gut) and GIP (glucose-dependent insulinotropic polypeptide, secreted by K-cells in the duodenum). Together they account for 50–70% of the insulin response to an oral glucose load — the 'incretin effect' defined by Nauck et al. in 1986. In people with type 2 diabetes, GLP-1 secretion is reduced and GIP response is impaired, which is why pharmacological incretin mimetics that target these receptors are a major therapeutic class.

What does retatrutide do differently from older incretin mimetics?

Retatrutide adds glucagon receptor agonism to the GLP-1R + GIPR combination established by tirzepatide. Glucagon receptor activation increases hepatic glucose output, thermogenesis, and resting energy expenditure — a caloric-expenditure mechanism that adds to the caloric-intake suppression from GLP-1R/GIPR. In Phase 3 trials, this translates to approximately double the weight reduction of first-generation GLP-1 agonists at comparable timepoints. Retatrutide is investigational (no FDA approval as of July 2026). Titan supplies it as a research-use-only compound.

Are incretin mimetics the same as peptide weight loss drugs?

Pharmacologically, approved incretin mimetics (semaglutide, tirzepatide) are peptide-derived drugs studied for weight management, and retatrutide is a peptide in Phase 3. However, the RUO research market and the clinical prescription market are entirely separate supply channels. Titan Peptide Lab's retatrutide is supplied as a lyophilized research-use-only compound for in-vitro laboratory research — not as a weight loss drug, not for human consumption, and with no efficacy claim for any condition. The clinical prescription drugs are available through licensed prescribers and pharmacies.

Does Titan sell semaglutide or tirzepatide?

No. Titan Peptide Lab does not stock semaglutide (Ozempic/Wegovy/Rybelsus) or tirzepatide (Mounjaro/Zepbound). These are FDA-approved prescription medications available through clinical supply channels. Titan stocks retatrutide ($199.99 RUO) as the investigational triple incretin agonist research compound.

Incretin mimetics · definition & mechanism · research use only

What are incretin mimetics — and how do GLP-1, GIP, and glucagon receptor agonists work?

Incretin mimetics are a pharmacological class of compounds that replicate or amplify the actions of incretin hormones — gut-derived peptides released after nutrient ingestion that potentiate glucose-dependent insulin secretion from pancreatic β-cells. The two primary incretin hormones are GLP-1 (glucagon-like peptide-1, secreted by L-cells of the distal small intestine and colon) and GIP (glucose-dependent insulinotropic polypeptide, secreted by K-cells of the duodenum and jejunum). In healthy physiology, these hormones account for 50–70% of the insulin response to an oral glucose load — an effect called the 'incretin effect' (Nauck et al. Diabetes 1986;35:430-433, PMID 3514343). Incretin mimetics — also called incretin receptor agonists or GLP-1 receptor agonists in the original single-receptor era — are exogenously administered compounds designed to occupy and activate these receptors with longer half-lives than the native hormones. The term 'mimetics' distinguishes them from DPP-4 inhibitors (which prevent degradation of endogenous incretins) by their mechanism: mimetics exogenously provide the receptor signal rather than protecting the endogenous one. This page is a research-context reference. Titan Peptide Lab stocks retatrutide — the triple GIP/GLP-1/glucagon incretin agonist currently in Phase 3 — as a research-use-only compound. Nothing on this page is clinical guidance.

Retatrutide — triple incretin agonist — $199.99 How does retatrutide work?

What is the incretin effect?

The incretin effect is the phenomenon where oral glucose provokes a substantially larger insulin response than the same amount of glucose administered intravenously — despite identical blood glucose levels. The difference is attributable to hormones secreted by gut endocrine cells in response to luminal nutrients. GLP-1 (glucagon-like peptide-1) is secreted by L-cells in the distal ileum and colon; GIP (glucose-dependent insulinotropic polypeptide, originally called 'gastric inhibitory polypeptide') is secreted by K-cells in the duodenum. Both hormones bind to receptors on pancreatic β-cells and potentiate glucose-stimulated insulin secretion in a glucose-dependent fashion — a critical feature meaning they amplify insulin release only when blood glucose is elevated, reducing hypoglycemia risk compared to non-glucose-dependent secretagogues.

Incretin peptides for obesity research →

Three generations of incretin mimetics

First generation (single GLP-1R agonists): exenatide (~2.4h t½, twice-daily), liraglutide (~13h, once-daily), semaglutide (~7d, once-weekly, or oral). These target GLP-1R only. Weight loss: liraglutide ~13% (Saxenda SCALE 2015), semaglutide ~15% (Wegovy STEP-1 2021). Second generation (dual GLP-1R + GIPR agonists): tirzepatide (~5d t½, once-weekly). Targets GLP-1R and GIP receptor simultaneously. Weight loss: tirzepatide ~22% (Zepbound SURMOUNT-1 2022). FDA-approved 2023 (Mounjaro T2D; Zepbound obesity 2023). Third generation (triple GLP-1R + GIPR + GcgR agonists): retatrutide (Eli Lilly, ~6d t½, once-weekly). Adds glucagon receptor. TRIUMPH-4 weight loss: ~28.7% at 68 weeks. Investigational as of July 2026.

Retatrutide vs tirzepatide →

What the glucagon receptor adds (third generation)

Glucagon receptor activation is mechanistically distinct from GLP-1R and GIPR agonism. Where GLP-1R suppresses appetite and GIPR improves insulin potentiation, the glucagon receptor drives thermogenesis and energy expenditure through hepatic glucose output, adipose tissue lipolysis, and increased resting metabolic rate (Conceição-Furber et al. Front Endocrinol 2022;13:868037). The critical point for incretin mimetic research is that the glucagon receptor adds a caloric-expenditure arm to the combination's mechanism — the body burns more energy — rather than only suppressing intake. This is the pharmacological explanation for why triple agonism appears to produce greater weight loss than dual agonism at comparable timepoints in clinical data. The challenge is that glucagon receptor activation also raises blood glucose (counteracting GLP-1-mediated lowering) and may cause heart rate elevation, both of which are tracked in the TRIUMPH safety program.

Triple agonist mechanism explained →

Clinical efficacy by generation

Generation 1 (GLP-1R only): liraglutide SCALE-1 ~13% weight loss at 56wk (Pi-Sunyer NEJM 2015;373:11-22); semaglutide STEP-1 ~14.9% at 68wk (Wilding NEJM 2021;384:989). Generation 2 (GLP-1R + GIPR): tirzepatide SURMOUNT-1 ~22.5% at 72wk for 15mg (Jastreboff NEJM 2022;387:205-216). Generation 3 (GLP-1R + GIPR + GcgR): retatrutide TRIUMPH-4 ~28.7% at 68wk (December 2025); TRIUMPH-1 up to ~30% at 104wk (May 2026). The consistent pattern: each additional receptor arm adds approximately 5–8 percentage points of weight reduction, suggesting true mechanistic additivity from the receptor combinations. These are research pharmacology data; no clinical recommendation is made.

Retatrutide Phase 3 results →

Incretin mimetics in the research compound space

FDA-approved incretin mimetics (semaglutide, tirzepatide, liraglutide) are prescription medications available through the clinical supply chain. Investigational incretin mimetics in Phase 3 (retatrutide, cagrilintide/CagriSema) are not approved and are available only through clinical trial enrollment or — in the RUO research space — as research-use-only compounds from specialized laboratory suppliers. Titan Peptide Lab supplies retatrutide as a lyophilized research-use-only vial ($199.99) for in-vitro laboratory research. Titan does not stock semaglutide or tirzepatide in any formulation. The RUO supply channel and the clinical/prescription channel are entirely separate.

Retatrutide RUO vial →

Incretin mimetics vs GLP-1 receptor agonists — is there a difference?

The two terms have overlapping but distinct scope. 'GLP-1 receptor agonists' (GLP-1RA) strictly refers to compounds that activate the GLP-1 receptor — this was the accurate term for the first-generation class (exenatide, liraglutide, semaglutide). When dual agonists (tirzepatide, GLP-1R + GIPR) and triple agonists (retatrutide, GLP-1R + GIPR + GcgR) emerged, the term 'GLP-1 receptor agonist' became technically inaccurate for those compounds since they also activate other receptors. 'Incretin mimetics' or 'incretin receptor agonists' is a broader term that encompasses all compounds in this mechanistic class regardless of the number of receptors targeted. In practice, the terms are often used interchangeably, with the specific receptor profile always being the more precise descriptor.

Ozempic (GLP-1 agonist) vs retatrutide →

The detail, in plain terms

Incretin mimetic generations at a glance.

Three generations of incretin receptor targeting with progressively higher efficacy in Phase 3 weight-loss trials. Research use only — prescription approvals and RUO supply channels are separate.

Native incretins: GLP-1 (L-cells, distal gut) and GIP (K-cells, duodenum) — both ~1–2 min plasma half-life endogenously; degraded by DPP-4.
Gen 1: GLP-1RA: Single GLP-1R. Liraglutide ~13h/daily, ~13% weight loss; semaglutide ~7d/weekly, ~15% weight loss. FDA-approved.
Gen 2: Dual GIP+GLP-1: GLP-1R + GIPR. Tirzepatide ~5d/weekly, ~22% weight loss. FDA-approved (Mounjaro T2D 2022; Zepbound obesity 2023).
Gen 3: Triple GIP+GLP-1+GcgR: GLP-1R + GIPR + glucagon receptor. Retatrutide ~6d/weekly, ~28.7% at 68wk (TRIUMPH-4 2025). Investigational.
Added mechanism per generation: Gen 1→2: GIP potentiates GLP-1 insulin effect, may reduce nausea. Gen 2→3: glucagon receptor adds thermogenesis + energy expenditure.
Titan supply: Retatrutide RUO lyophilized vial $199.99. Semaglutide/tirzepatide/liraglutide: NOT stocked.

Questions researchers ask

Before you order.

What is the difference between incretin mimetics and GLP-1 receptor agonists?: GLP-1 receptor agonists (GLP-1RA) is the original term for compounds activating the GLP-1 receptor specifically. 'Incretin mimetics' is a broader class term covering all compounds that mimic incretin hormone actions, including dual agonists (GLP-1R + GIPR, e.g. tirzepatide) and triple agonists (GLP-1R + GIPR + GcgR, e.g. retatrutide). In research literature, 'incretin receptor agonist' is increasingly preferred for multi-receptor compounds to avoid the inaccuracy of calling a dual or triple agonist just a 'GLP-1 receptor agonist.' In practice, both terms appear for semaglutide/liraglutide (single receptor), while tirzepatide and retatrutide are usually called dual or triple agonists rather than GLP-1RAs.
What is an incretin?: An incretin is a gut hormone released after nutrient ingestion that stimulates insulin secretion in a glucose-dependent manner (only when blood glucose is elevated). The two main incretins are GLP-1 (glucagon-like peptide-1, secreted by L-cells in the distal gut) and GIP (glucose-dependent insulinotropic polypeptide, secreted by K-cells in the duodenum). Together they account for 50–70% of the insulin response to an oral glucose load — the 'incretin effect' defined by Nauck et al. in 1986. In people with type 2 diabetes, GLP-1 secretion is reduced and GIP response is impaired, which is why pharmacological incretin mimetics that target these receptors are a major therapeutic class.
What does retatrutide do differently from older incretin mimetics?: Retatrutide adds glucagon receptor agonism to the GLP-1R + GIPR combination established by tirzepatide. Glucagon receptor activation increases hepatic glucose output, thermogenesis, and resting energy expenditure — a caloric-expenditure mechanism that adds to the caloric-intake suppression from GLP-1R/GIPR. In Phase 3 trials, this translates to approximately double the weight reduction of first-generation GLP-1 agonists at comparable timepoints. Retatrutide is investigational (no FDA approval as of July 2026). Titan supplies it as a research-use-only compound.
Are incretin mimetics the same as peptide weight loss drugs?: Pharmacologically, approved incretin mimetics (semaglutide, tirzepatide) are peptide-derived drugs studied for weight management, and retatrutide is a peptide in Phase 3. However, the RUO research market and the clinical prescription market are entirely separate supply channels. Titan Peptide Lab's retatrutide is supplied as a lyophilized research-use-only compound for in-vitro laboratory research — not as a weight loss drug, not for human consumption, and with no efficacy claim for any condition. The clinical prescription drugs are available through licensed prescribers and pharmacies.
Does Titan sell semaglutide or tirzepatide?: No. Titan Peptide Lab does not stock semaglutide (Ozempic/Wegovy/Rybelsus) or tirzepatide (Mounjaro/Zepbound). These are FDA-approved prescription medications available through clinical supply channels. Titan stocks retatrutide ($199.99 RUO) as the investigational triple incretin agonist research compound.